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Abstract
Dysfunctional RNA-binding proteins (RBPs) have been implicated in several neurodegenerative disorders. Recently, this 
paradigm of RBPs has been extended to pathophysiology of Alzheimer’s disease (AD). Here, we identified disease subtype 
specific variations in the RNA-binding proteome (RBPome) of sporadic AD (spAD), rapidly progressive AD (rpAD), and 
sporadic Creutzfeldt Jakob disease (sCJD), as well as control cases using RNA pull-down assay in combination with proteom-
ics. We show that one of these identified proteins, splicing factor proline and glutamine rich (SFPQ), is downregulated in the 
post-mortem brains of rapidly progressive AD patients, sCJD patients and 3xTg mice brain at terminal stage of the disease. 
In contrast, the expression of SFPQ was elevated at early stage of the disease in the 3xTg mice, and in vitro after oxidative 
stress stimuli. Strikingly, in rpAD patients’ brains SFPQ showed a significant dislocation from the nucleus and cytoplasmic 
colocalization with TIA-1. Furthermore, in rpAD brain lesions, SFPQ and p-tau showed extranuclear colocalization. Of 
note, association between SFPQ and tau-oligomers in rpAD brains suggests a possible role of SFPQ in oligomerization and 
subsequent misfolding of tau protein. In line with the findings from the human brain, our in vitro study showed that SFPQ is 
recruited into TIA-1-positive stress granules (SGs) after oxidative stress induction, and colocalizes with tau/p-tau in these 
granules, providing a possible mechanism of SFPQ dislocation through pathological SGs. Furthermore, the expression of 
human tau in vitro induced significant downregulation of SFPQ, suggesting a causal role of tau in the downregulation of 
SFPQ. The findings from the current study indicate that the dysregulation and dislocation of SFPQ, the subsequent DNA-
related anomalies and aberrant dynamics of SGs in association with pathological tau represents a critical pathway which 
contributes to rapid progression of AD.
Keywords RNA-binding proteins · Rapidly progressive Alzheimer’s disease · SFPQ · Stress granules · Dislocation · 3xTg 
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Introduction
Alzheimer’s disease (AD) is the most prevalent form of 
dementia with progressive neurodegeneration, affecting 
more than 40 million people worldwide [57, 61]. Typically, 
sporadic AD cases are characterized by a slow progression 
in cognitive decline and a disease duration of ~ 8 years after 
the onset of clinical symptoms [66]. However, mounting 
evidence show variability in both clinical phenotypes and 
progression rates [1, 6, 21, 68]. Recently, a rapidly progres-
sive form of AD (rpAD) has been identified with a steep 
decline in Mini-Mental State Examination (MMSE: a psy-
chometric test) score (e.g. ≥ 5 points/year), and/or a reduced 
disease duration (~ 4 years) [47, 54, 67, 74, 82]. The clinical 
definition of rpAD differs greatly across various studies in 
the literature. Preliminary evidence provide a compelling 
view that rpAD is associated with a distinct molecular and 
pathogenic cascade [6, 21, 26]. However, no significant dif-
ferences have been detected in the core neuropathological 
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features between spAD and rpAD [21, 68], suggesting a 
great demand for understanding of underlying pathogenic 
mechanisms responsible for this heterogeneity. Rapidly 
progressive AD cases exhibit a partial clinical overlap with 
sporadic CJD, another rapidly progressive dementia, which 
makes early differential diagnosis a challenge [1, 68, 75]. 
The identification of the common pathogenic mechanisms 
and molecular factors that lead to faster progression, may be 
of common therapeutic interests [83].
Extracellular Aβ plaques and intracellular neurofibril-
lary tangles (NFTs) of hyperphosphorylated tau protein 
are two cardinal features of AD. The amyloid hypothesis 
proposes Aβ pathology as the principal pathological fea-
ture of the disease [32] that triggers a cascade of additional 
pathological events, including the formation of NFTs, neu-
roinflammation, oxidative stress and neuronal loss [32, 62, 
78]. Recent evidence suggests a novel pathological feature 
of tau, in relation to cytoplasmic stress granules (SGs) and 
RNA-binding proteins (RBPs), through which tau disrupts 
cellular homeostasis. RBPs, like TIA-1, co-localize with 
hyperphosphorylated-tau and aggravate tau pathology [85, 
86]. SGs are reversible cytoplasmic aggregates composed 
of RBPs, RNA and stalled translation initiation complexes 
that usually resolubilize after removal of stress [3, 38]. The 
association of several RBPs with AD and other neurologi-
cal diseases redirects research efforts toward understanding 
the role of RBPs in neurodegeneration and progression of 
these diseases. To this end, this study aimed to identify and 
characterize RNA-binding proteome (RBPome) variations 
in subtypes of Alzheimer’s and prion disease (sCJD), to find 
out potential candidates underlying phenotypic heterogene-
ity and variant progression rates at molecular level.
The proteomic investigation, in combination with sev-
eral bioinformatic and computational approaches high-
lighted quantitative and qualitative changes in the identified 
RBPome, in a disease subtype specific manner. Here, we 
show that one of these identified proteins- splicing factor 
proline and glutamine rich (SFPQ), is dysregulated in asso-




Frontal cortex samples from spAD, rpAD and age-matched 
controls were provided by Institute of Neuropathology Brain 
Bank (HUB-ICO-IDIBELL Biobank) and Biobank of Hospi-
tal Clinic-IDIBAPS Spain, following the legislation (Ley de 
la Investigación Biomédica 2013 and Real DecretoBioban-
cos, 2014) and the approval of local ethics committees. Fron-
tal cortex samples from patients with sCJD subtypes (-MM1 
& -VV2) were obtained from the Department of Neurology 
at the University Medical Centre, Göttingen, Germany. Eth-
ics approval was obtained from the Ethical Committees of 
the University Medical Centre, Göttingen, Germany and all 
the procedures were conducted in accordance to ethics regu-
lations (Nr. 1/11/93 and Nr. 9/6/08).
All animal experiments were conducted according to 
the ethical standards of the Regierungspräsidium Tübingen 
(Regional Council) experimental no. FLI 231/07 file ref-
erence number 35/9185.81-2. All procedures were carried 
out in accordance with the institutional and French national 
guidelines within the European Community Council Direc-
tive 86/609/EEC. The experimental procedures approved 
by the INRA Toulouse/ENVT ethics committee were used.
Patient cohorts and rpAD/spAD/sCJD subtype 
characterization
Patient cohort processing, neuropathological examination 
and brain tissue collection for this study were all conducted 
as previously described [90, 91]. The post‐mortem interval 
was between 3 and 18 h. Both spAD and rpAD samples had 
AD pathologies with Braak stage ≥ V. The samples for AD 
subtypes were included without co-pathologies. Likewise, 
the sCJD subtypes (sCJD-MM1 & -VV2) were exclusively 
composed of prionopathies. Details of the patient cohorts are 
described in the supplementary tables (suppl. Tables 4 and 
5, online resource). Diagnosis of all the control and spAD 
cases is described in detail by Hernandez et al. [33]. All 
the cases were confirmed by neuropathological examination 
of 25 regions of the cerebral cortex, thalamus, diencepha-
lon, cerebellum and brainstem as described previously [33]. 
Haematoxylin and eosin, Klüver-Barrera and immunohis-
tochemistry (for glialfibrillary acidic protein, β-amyloid, 
phosphorylated tau, α-synuclein, TDP 43, ubiquitin, p62 
and microglial specific markers) were performed [33]. Neu-
ropathological assessment of spAD was done following 
the Braak and Braak stages [16–18]. All rpAD cases met 
the current criteria of rpAD [21]. Braak stages of NFT and 
plaque pathology: I-VI/0-C, and Thal phases 1–5 [80] of all 
the cases are described in the supplementary table (suppl. 
Table 4, online resource). There were no significant differ-
ences observed in the age distribution (suppl. Figure 1a, 
online resource).
Humanized mice model of combined Aβ and tau 
pathology (3xTg)
The mouse model (3xTg) was initially generated and charac-
terized by Oddo et al. [58]. Transgenic mice between 3 and 
4 months of age were inoculated with10% brain homoge-
nate from AD patient (Case no. 10 in the suppl. Table 4, 
online resource), in the thalamus. The cortical brain tissue 
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was homogenized in PBS. After centrifugation, supernatant 
was transferred to new tube and 20 μL of the supernatant 
was used for inoculation. All 3xTg-mice inoculated (AD) 
and non-inoculated (controls) were sacrificed and brains 
were collected at 4 time-points corresponding to 3-, 6-, 9- 
and 12-months post-inoculation (mpi). All the mice (n = 48) 
were anesthetized and decapitated. The cortical tissues were 
obtained and immediately stored in liquid nitrogen for fur-
ther analysis.
RNA extraction and tissue lysis for pull‑down assay
Before RNA extraction, surfaces and lab-ware were cleaned 
with RNAseZap (Thermo Fischer Scientific). Total RNA 
was isolated, from the human brain frontal cortices of spAD, 
rpAD, sCJD and control cases, using RNeasy Plus Univer-
sal kits (Qiagen, Germany), including DNAse treatment 
in accordance with the manufacturer’s instructions. The 
concentration of RNA was measured using a NanoDrop 
2000 (Thermo Scientific). The integrity of isolated RNA 
was confirmed with the Bioanalyzer (Agilent Technologies, 
Santa Clara, CA). All the samples bearing RNA integration 
number (RIN) ≥ 5 were selected for downstream analysis. 
Frontal cortex tissues from same cases were lysed in ‘’tissue 
protein extraction reagent’’ (T-PER; Thermo Fischer Scien-
tific), supplemented with phosphatase and protease inhibitor 
cocktails (Roche, Germany). The concentration of protein 
extracts was determined using Bradford assay (Bio-Rad, 
Germany). The concentration of total protein extract was 
kept greater than 2 mg/mL, such that there is a significant 
dilution into the binding reaction buffer.
RNA pull‑down assay
Total brain-derived RNA was labelled with desthiobiotin 
at 3′- end using T4-RNA ligase from Pierce RNA 3′-End 
Desthiobiotinylation Kit, which were a part of the Pierce™ 
Magnetic RNA–protein pull-down kit (Thermo Fisher Sci-
entific). The labelling efficiency of experimentally labelled 
samples (diseased and control) was assessed by dot blotting 
[(Thermo Scientific Chemiluminescent Detection Module 
(Product No. 89880)], according to instructions from the 
manufacturer. Desthiobiotinylated RNA was used for the 
enrichment of RNA-binding protein complexes, according 
to the manufacturer’s recommendations (Thermo Fischer 
Scientific). Isolated protein complexes were eluted with 
biotin elution buffer and processed for mass spectrometry 
(MS) analysis (Fig. 1a). In this assay, streptavidin magnetic 
beads were mixed with protein extracts in the absence of 
biotinylated transcript as a control for nonspecific bind-
ing. A combination of bioinformatic, computational, and 
biochemical approaches was used to comprehensively ana-
lyse the isolated RBPome (Fig. 1b).
Label‑free quantification mass spectrometry 
(LFQ‑MS) analysis
Mass spectrometry analysis was performed as published 
previously [90]. Briefly, isolated protein complexes were 
resolved onto 4–20% Bis–Tris gels (NuPAGE Novex 
Bis–Tris Mini gels, Invitrogen) for a length of ~ 1 cm and 
stained with Coomassie stain. The bands were sliced into 
small cubes (1–2  mm2). The digestion of proteins into pep-
tides, identification and quantification of these peptides was 
carried out as described previously. Scaffold (version Scaf-
fold_4.8.4, Proteome Software Inc., Portland/OR, USA) was 
used to validate MS/MS based peptide and protein identifi-
cations. Threshold for peptide identifications was established 
at greater than 95% confidence. For protein identifications, 
a minimum of 2 peptide count and a confidence threshold 
of 99% was used. Protein probabilities were allotted by the 
Protein Prophet algorithm [55].
Co‑immunofluorescence
Formalin fixed and paraffin embedded human brain cortical 
sections (5 µm thick) from spAD, rpAD and age matched 
controls were analysed by co-immunofluorescence using 
protocols validated previously [42, 86]. Imaging was per-
formed with confocal laser scanning microscope TCS-SPE 
(Leica, Germany; 543 and 633 nm helium–neon and 488 nm 
argon excitation wavelengths). All images were separately 
analysed for colocalization using ImageJ (WCIF plugin) 
and FIJI (coloc 2) software. Threshold Mander’s overlap 
coefficients (tM1 & tM2) and Pearson’s linear correlation 
coefficient (rP) were calculated to measure the strength and 
direction of linear correlations between two fluorescence 
channels. In addition, intensity correlation analysis (ICA) 
was also performed [43].
Cell model for stress induction
Confluent cells (HeLa, SH-SY5Y and HEK-293) were sub-
jected to oxidative stress by adding a pre-warmed culture 
medium containing sodium arsenite (0.6 mM) for 1 h at 
37 °C. After one hour of treatment, the cells were either 
fixed with 4% paraformaldehyde (PFA) for immunocyto-
chemistry or proceeded for immunoblotting analysis.
Tau‑transfections
Plasmids for human wild type-tau (pRK5-EGFP-tau) and 
mutated-tau (pRK5-EGFP-tau P301L) were obtained 
from Addgene. The plasmids were propagated in E. coli. 
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DH5alpha strain and were extracted for the transfection 
assay using the Hispeed Plasmid Midi kit (Qiagen, Ger-
many). Transient transfections were achieved using Lipo-
fectamine 2000 (Invitrogen) reagent according to the instruc-
tions of the manufacturer. HeLa cells (2 × 105/well) were 
plated in 6-well plates and cultured for 24 h in the culture 
medium. The cells were washed with Opti-MEM I, followed 
by transfection with 2 μg of DNA/well in the Opti-MEM I 
medium. The cells were harvested from cultures after 24- 
and 48-h post-transfection followed by immunoblotting 
and SWATH-MS (Sequential Windowed Acquisition of All 
Theoretical Fragment Ion Mass Spectra) analysis (detailed 
protocol is provided in supplementary Material, online 
resource).
Statistical analysis
All the data in the present study was obtained after perform-
ing at least three independent experiments. All the results are 
described as mean ± SEM (standard error of the mean). The 
Fig. 1  Identification of RNA-
binding proteins by RNA 
pull-down assay and mass spec-
trometry analysis. a Total RNA 
was isolated from the human 
brain frontal cortical region of 
20 cases (spAD, rpAD, sCJD-
MM1, sCJD-VV2 as well as 
controls). Bead-only control was 
used for non-specific binding. 
Isolated protein complexes were 
identified quantitatively using 
MS/MS analysis. In total, 1091 
proteins were identified and 
quantified at a minimum peptide 
count of 2 and a protein thresh-
old of 99%. b Target selection 
from proteomic investigation 
and their pathological charac-
terization in the post-mortem 
human brains: a combination 
of bioinformatic and computa-
tional approaches was used to 
find out significant hits from 
the proteomic study, including 
differential enrichment analysis 
of MS data, hierarchical cluster-
ing analysis to visualize global 
proteome profile, comparative 
RBPome analysis, Gene Ontol-
ogy (GO) functional enrichment 
analysis, database search for 
identification of bona-fide and 
novel/putative RBP candidates, 
and prion-like domain scanning 
with PLAAC database. Target 
candidates prioritized from 
proteomic study were pathologi-
cally characterized in the post-
mortem human brain, using 
various techniques including 
immunoblotting, qRT-PCR and 
immunohistochemical analysis
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densitometry analysis of immunoblots was performed with 
Image Lab software (version 3.0.1). Statistical tests were 
applied using GraphPad Prism 6.01. The data from mass 
spectrometry analysis were analysed using the Perseus soft-
ware. Hierarchical clustering analysis was also performed 
with Perseus software. Two-dimensional interaction plots 
were plotted in R (version 3.4.3), followed by editing using 
Inkscape (version 0.92). For comparisons between two 
groups, the student’s t-tests or Welch’s t-tests were used. 
For comparisons between three or more groups, a one-way 
ANOVA followed by the Tukey post-hoc analysis was used 
unless otherwise stated in the text. Statistical significance 
was considered for a p-value < 0.05.
Results
Global enrichment profile of RNA‑binding protein 
candidates
Emerging evidence demonstrate that numerous neurode-
generative disorders, including AD display RBP patholo-
gies, highlighting a vital role of RBPs in neurodegeneration 
[23, 52, 86]. In the present study, using brain-derived total 
RNA based pull-down approach in combination with label 
free quantitative proteomics, we identified subtype specific 
variations in the RBPome from the human brain of spAD, 
rpAD and sCJD. Differential enrichment analysis of RBP-
candidates revealed 338 proteins with significant differences 
(p < 0.05) in abundance between any of the experimental 
groups (Fig. 2a–f, and suppl. Table 11, online resource). 
Using significantly enriched proteins in the hierarchical 
clustering analysis, four different expression signatures were 
identified, which are represented in the form of heatmap 
(Fig. 2g). Based on RBP-signatures, rpAD and sCJD groups 
appeared largely similar as they were segregated into a sin-
gle cluster, whereas both were different from the control 
group (Fig. 2g). The control and spAD cases were segre-
gated into a separate cluster based on the full set of differ-
entially enriched proteins, which indicated similarities in the 
protein profiles between control and spAD groups. Overall, 
clustering of the individual replicates indicated low biologi-
cal variance and segregation of all the groups, showing the 
reproducibility and robustness of the workflow (Fig. 2g).
The proteins which were specifically enriched in each 
group were used to find out a comparative proteome pro-
file of the RBP-candidates. This analysis revealed disease-
subtype specific differences in the enriched RBP-candidates 
(Fig. 3a). There were 98 proteins that were shared among 
all the groups. The common and unique proteins from all 
the groups are shown in Fig. 3a (suppl. Table 6, online 
resource).
Functional categorization of RBP candidates
To gain functional insights into the identified RBP candi-
dates, classification based on gene ontology (GO) anno-
tations (biological process and molecular function) was 
performed. Based on clustering of GO-terms, rpAD and 
sCJD groups were segregated into a single cluster, showing 
similarities in the enriched functional-terms (Fig. 3b). The 
most enriched functional categories for both groups included 
RNA binding, antioxidant activity, immune system process 
and response to stress (e.g. response to oxidative stress, cel-
lular response to stress) among others (Fig. 3b). The signal 
transducer activity was particularly enriched in the spAD 
group when compared with other groups. Additionally, one 
cluster of cellular processes (including transporter activity, 
cellular homeostasis, localization and binding) was particu-
larly enriched in the rpAD group, showing more aggressive 
disturbances in the overall cellular homeostasis in the rpAD 
group.
Classification of known and putative‑RBP candidates
In order to discriminate bona-fide RBPs from putative RBP 
candidates, identified proteins were classified, as demon-
strated previously [11]. Two classes were organized to give 
clarity to the data (Fig. 4a). The class I (bona-fide RBP can-
didates: red bars) contains proteins that were having molec-
ular function annotation as RNA-binding. There were 64 
RBPs in the control group, 64 in spAD, 77 in rpAD and 
70 in sCJD that were annotated as RNA-binding proteins. 
The class II (putative-RBP candidates: black bars) (Fig. 4a) 
contains the rest of the proteins, which include metabolic 
and catalytic enzymes among others. It should be noted that 
some of the identified candidate proteins may not have RNA-
binding activity themselves, but, instead, interact with other 
proteins that do, and are hence identified in the RBPome.
Prion‑like domain (PLD) prediction
Prion-like domains (PLD) are often present in the RBPs 
that carry out protein aggregation in neurodegenerative dis-
eases, e.g. amyotrophic lateral sclerosis (ALS) and, more 
recently, in Alzheimer’s disease [40, 86, 87]. To evaluate 
the presence and biological significance of PLD-containing 
proteins in our dataset, identified RBP candidates were ana-
lysed using highly-stringent computational algorithms [81, 
92]. We used an updated web-based PLAAC (Prion Like 
Amino Acid Composition) database to identify proteins with 
prion-like amino acid composition in our data-set. Crite-
ria for a protein to have a PLD consisted of four require-
ments: it had to (1) be rich in Q/N-sequences, (2) exhibit 
disorderliness (according to PAPA algorithm) [60], (3) have 
compositional similarity with yeast prion domains, and (4) 
322 Acta Neuropathologica (2020) 140:317–339
1 3
contain short amyloidogenic stretches able to carry out their 
self-assembly into an amyloidogenic state. Applying these 
criteria, we identified 24 PLD-containing proteins in the cur-
rent study (suppl. Table 3, online resource). PLD of one of 
these proteins (SFPQ) is shown in Fig. 4b. Given that, SFPQ 
exhibited quite high PLD score, we further identified the 
amyloidogenic stretch in the sequence of SFPQ with algo-
rithm ArchCandy (suppl. Figure 4, online resource).
Pathological characterization of target RBP– SFPQ– 
in the postmortem brains
From the PLD-containing proteins described in the suppl. 
Table 3 (online resource), we selected SFPQ based on spe-
cific enrichment of this protein in rapidly progressive forms 
of dementia (rpAD and sCJD). Further, SFPQ exhibited a 
high score for PLD, which is a very crucial factor contribut-
ing to the pathophysiology of RBPs. TIA-1 (T-cell intra-
cellular antigen 1) was also added as a target candidate for 
further investigation, given that its role in tau-aberrations in 
Fig. 2  Global enrichment 
profile of RBPome candidates 
isolated from the human brain 
frontal cortical region of 20 
cases (spAD, rpAD, sCJD-
MM1, sCJD-VV2 as well as 
controls). a–f Volcano plots of 
pairwise comparisons (t-tests 
with BH correction) showing, 
the -log10-p-values (y-axis) and 
the log2(FC) of the proteins 
that were significantly abundant 
(x-axis) in all the group combi-
nations (spAD vs control, rpAD 
vs control, sCJD vs control, 
spAD vs rpAD, rpAD vs sCJD, 
and spAD vs sCJD). The data 
points above the dashed lines 
represent proteins having a 
p-value < 0.05 and FC >  ± 1.5 as 
significant hits and are depicted 
in red (for enriched) and blue 
(for depleted). g The heatmap 
(hierarchical clustering analysis) 
showing significantly-enriched 
proteins. The Log2-transformed 
expression values of proteins 
were normalized by Z-score 
for each biological replicate. 
Horizontal-axis indicates the 
differentially-enriched proteins, 
and the vertical axis shows the 
biological replicates from all the 
groups. Blue denotes depleted 
proteins, red represents enriched 
proteins
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AD [4], although it was not detected in our MS dataset (most 
likely due to hydrophobic nature of the protein).
In order to explore specific mechanisms by which our 
selected target candidates (particularly SFPQ) are involved 
in the disease pathogenesis, and to further ascertain whether 
our selected approaches were appropriate for target selec-
tion, we began to analyze these proteins in more detail.
SFPQ and TIA‑1 are dysregulated in rpAD and sCJD brains
As neurons are very sensitive to aberrant dosage and dynam-
ics of RBPs [22], firstly we investigated the differential 
expression of SFPQ and TIA-1 in the human brain. Immu-
noblotting analysis was performed in the frontal cortical 
brain tissues from spAD, rpAD, sCJD-MM1, and sCJD-VV2 
subtypes, as well as non-demented controls. The expres-
sion of SFPQ was reduced in the frontal cortex of rpAD 
(Fig. 5a, b) and sCJD subtypes (suppl. Figure 2a, b, online 
resource), compared with controls. A significant reduction 
was observed for TIA-1 levels in the spAD cases (Fig. 5a, 
c) and both subtypes of sCJD (-MM1 & -VV2) (suppl. Fig-
ure 2a, c, online resource), in comparison to control cases. 
In contrast, the levels of TIA-1 were significantly elevated 
in rpAD group in comparison to spAD group (Fig. 5a, c).
Dysregulation of SFPQ and TIA-1 at protein level 
prompted us to investigate their expression at the mRNA 
level. Quantitative RT-PCR analysis was performed to 
examine mRNA levels. Contrary to a reduced expression 
at the protein level in rpAD brains, SFPQ was significantly 
elevated at mRNA level, in comparison to control and 
spAD groups (Fig. 5d). For TIA-1 mRNA levels, a signifi-
cant increase was observed in rpAD cases, in line with an 
increase at protein level (Fig. 5e).
SFPQ dislocation and colocalization with SG marker TIA‑1 
in the rpAD brain
Mislocalization of RBPs has been identified as a pathologi-
cal feature in several neurodegenerative disorders [10, 12, 
56, 84]. Next, we sought to explore the localization of SFPQ 
in postmortem brains. In order to study the localization of 
SFPQ, we immuno-stained the frontal cortical brain tissues 
from spAD, rpAD, and control cases. In most cells of the 
control and spAD brains, SFPQ was localized in the nucleus, 
the typical localization of SFPQ, as reported previously [53]. 
The typical cells were zoomed-in for closer details (see 
Fig. 5f, right panel). Strikingly, in rpAD cases, a massive 
dislocation of SFPQ was identified from the nucleus. A ring-
shaped SFPQ was observed around the nuclei (see arrows 
in Fig. 5f, zoom-in section). A higher dislocation rate was 
observed in rpAD cases (91% cells), in comparison to spAD 
(51%) and control cases (43%) (Fig. 5g). These results indi-
cate that nuclear depletion and dislocation of SFPQ occurred 
in both control and patient brains; however, the dislocation 
rate was particularly higher in rpAD brains.
Recently, mislocalization of some nuclear factors has 
been related to their cytoplasmic accumulation in the SGs 
[10, 84]. To test this possibility, we used co-immunofluo-
rescence with primary antibodies specific for SFPQ (red) 
and TIA-1 (green): a classical marker of SGs (Fig. 5f). 
Sudan black was used to quench lipofuscin fluorescence, 
Fig. 3  Comparative RNA-binding proteome profiling and functional 
categorization of MS results. RNA-binding proteome was isolated 
and identified from the human brain frontal cortical region of 20 
cases (spAD, rpAD, sCJD-MM1, sCJD-VV2 as well as controls). a 
Venn diagram representing unique and shared RBP candidates in all 
groups. b Functional classification of MS results: RBP candidates 
identified in each group were analysed for associated Gene ontology 
functional-terms in two domains “biological process and molecular 
function’’. The protein counts associated with GO-terms from each 
group were uploaded to Perseus software, to prepare heatmap show-
ing relative enrichment of different functional categories across all 
the groups. The variation in each term across the groups was cal-
culated by Z-score. The columns of heatmap are representing dis-
ease groups (vertical-axis) and rows are displaying functional terms 
(x-axis), with red indicating an enriched category as compared with 
other groups, and green indicating depleted terms
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as differentiation of SG reactivity from lipofuscin can be 
quite challenging [46, 86]. TIA-1 immunoreactivity was 
also observed in control cases and a partial colocalization 
was also observed with SFPQ (Fig. 5f, zoom-in section). 
In spAD cases, a moderate colocalization was observed. 
For rpAD cases, a significant colocalization was identified 
between SFPQ and TIA-1 in the perinuclear/cytoplasmic 
area (Fig. 5f, zoom-in panel).
Multiple methods were used to provide a quantitative 
measure of the extent of colocalization between SFPQ and 
TIA-1, using FIJI (Coloc2) and image J (WCIF plugin) soft-
ware. We examined the colocalization between SFPQ and 
TIA-1 using Pearson’s correlation coefficient (rP), Threshold 
Mander’s coefficients (tM1, tM2) [14], and intensity cor-
relation analysis (ICA). ICA (PDM plots) showed highest 
degree of colocalization between SFPQ and TIA-1 in the 
rpAD brains, followed by spAD and controls (Fig. 5f, right 
panels). A significant degree of colocalization was observed 
in rpAD cases, compared with spAD, by both colocalization 
coefficients (rP and tM) (Fig. 5h, i). The value of tM1 shows 
the overlap of TIA-1 channel pixels with SFPQ channel pix-
els, which is significantly higher in rpAD when compared 
with either spAD or control cases. For tM2 (representing the 
overlap of SFPQ channel pixels with TIA-1 channel pixels), 
an increasing trend was also observed for rpAD cases. In 
summary, quantitative analysis of the co-immunofluores-
cence demonstrated that, colocalization between SFPQ and 
TIA-1 can be observed in both control and patients, with a 
specifically stronger degree of colocalization in rpAD cases.
SFPQ is colocalized with p‑tau and oligomeric‑tau 
in the rpAD brain
Cytoplasmic co-aggregation of some splicing factors with 
tau protein has been reported in both sporadic and familial 
cases of AD [7, 25, 85]. To test this possibility, we stud-
ied the relationship of SFPQ with tau-tangles using immu-
nohistochemical analysis. A change in the fluorescence 
Fig. 4  Identification of canoni-
cal and putative RBP candi-
dates. RNA-binding protein 
candidates were isolated and 
identified from the human brain 
frontal cortical region of 20 
cases (spAD, rpAD, sCJD-
MM1, sCJD-VV2 as well as 
controls). a The identified prot-
eomic candidates were searched 
for RNA-binding annotation 
in the UniProtKB database. 
The bar graph is representing 
two categories. The category I 
(red) indicates canonical RBPs 
(known), and category II (black 
bar) represents potential novel/
putative RBP candidates from 
each group. b Identification of 
SFPQ-prion-like domain by 
PLAAC database. The amino 
acid sequence of SFPQ is 
represented in colour coded 
boxes. The red line in the top 
panel represents the probability 
of a prion domain against the 
background. The plots in the 
middle panel show fold-index 
scores in grey [60], the log-
likelihood (LLR) ratio scores 
in red [2], and the predicted 
prion propensity (PPP) in green 
[81]. Negative scores represent 
disorder and prion propensity, 
dashed green line is indicating 
the cutoff value of PPP > 0.05. 
The bottom panel is showing 
the primary sequence of SFPQ 
with PLD in red colour [2]
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Fig. 5  Differential expression analysis of SFPQ and TIA-1 at protein 
and mRNA level. a Representative immunoblot images. Immunoblot-
ting analysis was performed with frontal cortical human brain tissues 
from spAD (n = 8), rpAD (n = 6), sCJD (-MM1 & -VV2 subtypes, 
n = 8) and non-demented controls (n = 8). b, c The densitometric 
analysis of SFPQ and TIA-1. d, e Expression of SFPQ and TIA-1 at 
mRNA level was analysed in spAD, rpAD, and controls with qRT-
PCR (n = 5–8). GAPDH was used to normalize the expression levels 
of mRNA. The comparative Ct method  (2^−ΔΔCt) was used for cal-
culation of relative mRNA levels [45]. f Dislocation of SFPQ from 
the nucleus and colocalization with SG-marker-TIA-1. Co-immuno-
fluorescence of SFPQ (red) and TIA-1 (green) in the human brain of 
spAD (n = 4), rpAD (n = 4), and controls (n = 5). Cell nuclei were vis-
ualized with To-Pro-3 iodide staining (blue). Representative images 
are shown (scale bar = 50 um). Intensity correlation analysis (PDM 
plots) was performed with ImageJ (WCIF Plugin). g Quantification 
of the cells showing SFPQ dislocation/depletion (n = 150/group). h 
Pearson’s correlation coefficient (rP) graph, showing significant colo-
calization between SFPQ and TIA-1 in rpAD cases in comparison to 
spAD cases. i Colocalization analysis with Threshold Mander’s cor-
relation coefficients (tM1 & tM2). The value of tM1 represents the 
overlap of TIA-1 channel pixels with SFPQ channel pixels, and tM2 
represents the overlap of SFPQ channel pixels with TIA-1 channel 
pixels. The colocalization analysis was performed with FIJI software 
(Coloc 2). One-way ANOVA and Tukey post-hoc test for multiple 
comparisons was used to calculate significance, *p < 0.05, **p < 0.01
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pattern was observed for SFPQ and p-tau, and typical cells 
were zoomed-in for closer details. In the human brain of 
spAD patients, SFPQ immunopositivity was detected in the 
nucleus and for p-tau tangles in the cytoplasm, with an occa-
sional overlap between both in the nuclear region (Fig. 6a). 
In rpAD cases, two interesting findings were observed. 
Firstly, colocalization between SFPQ and p-tau was sig-
nificantly increased compared with spAD group (Fig. 6c). 
Secondly, this colocalization was extranuclear rather than 
colocalization in the nuclear region that was observed in 
spAD cases.
Although, accumulation of cytoplasmic tau-tangles is a 
burden for the cell, it has recently been demonstrated that 
toxic-soluble oligomeric species of tau are the real culprits 
associated with cognitive decline, neuronal dysfunction, 
and death [31, 70]. In order to investigate the association 
of SFPQ with oligomeric-tau, we co-immuno-stained the 
cortical sections from control, spAD and rpAD cases (given 
that a significant association of SFPQ with tau-tangles was 
observed in the rpAD brain) with SFPQ and anti-oligomeric 
antibody for tau (T-22). Almost no reactivity was observed 
for oligomeric-tau in the control cases (Fig. 6b). Interest-
ingly, the co-immunofluorescence analysis revealed a sig-
nificant colocalization between SFPQ and tau-oligomers in 
both spAD and rpAD cases (Fig. 6b). The degree of colo-
calization was estimated with ICA (PDM plots) and Thresh-
old Mander’s correlation coefficients (tM1, tM2) (Fig. 6d). 
Fig. 6  SFPQ colocalize with 
p-tau tangles and oligomeric-
tau in rpAD brains. a Rep-
resentative images stained 
with SFPQ (red) and α- p-tau 
(S199) (green) antibodies (scale 
bar = 50 μm) in spAD (n = 3) 
and rpAD (n = 3). Sections were 
counter stained with To-Pro-3 
iodide to visualize nuclei (blue). 
PDM plots were prepared by 
intensity correlation analysis 
(ICA) using Image-J (WCIF 
plug-in). b Co-immunofluo-
rescence images from control 
(n = 3), spAD (n = 5) and rpAD 
(n = 3) cortical sections, stained 
with α-SFPQ (red) and α-Tau 
oligomeric antibody: T-22 
(green). PDM plots showing 
colocalization. c Pearson’s 
correlation coefficient (rP) and 
threshold Mander’s correlation 
coefficients (tM1& tM2) repre-
senting significant colocaliza-
tion between SFPQ and p-tau in 
the rpAD group, in comparison 
to spAD group. Statistical 
significance was calculated by 
t-test, *p < 0.05, **p < 0.01, 
***p < 0.001. d Threshold Man-
der’s correlation coefficient’s 
(tM1, tM2) showing significant 
colocalization between SFPQ 
and oligomeric-tau in both 
spAD and rpAD, as compared 
with control. Graphs were 
prepared with GraphPad Prism 
(6.01) using One-way ANOVA 
and Tukey post-hoc test for mul-
tiple comparisons, **p < 0.01
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Significant colocalization was identified in both spAD and 
rpAD cases by both methods.
Role of SFPQ in stress response
In order to investigate the significance of SFPQ mislocaliza-
tion and association with the SG-marker TIA-1, a cellular 
model of stress was established in HeLa cells. A well-known 
oxidative stress-inducer, sodium arsenite, was used for stress 
induction. SGs were analysed, where the viability of stressed 
(arsenite treated) cells was not compromised (suppl. Fig-
ure 2h, online resource). After stress induction, cells were 
stained with a classical marker of SGs (TIA-1) to visualize 
SGs (Fig. 7a). Oxidative stress treatment induced the forma-
tion of clearly-defined cytoplasmic-foci positive for TIA-1 
staining in more than 80% of cells (Fig. 7a, d).
Previously, it has been reported that SGs play an impor-
tant role in tau aggregation [86]. Next, we examined the 
relationship between tau and SGs in our cellular model of 
stress by immunocytochemistry. Control (untreated) cells 
showed a positive signal for total-tau (tau-5) predominantly 
in the cytoplasm (suppl. Figure 3a, online resource). For 
p-tau (S199), a positive signal was detected in the cytosol 
and nucleus (suppl. Figure 3b,, online resource), with pre-
dominance in the nucleus, which is in-line with previous 
studies conducted in HeLa cells [36, 73]. Such a signal was 
increased upon oxidative stress induction. Stress treatment 
induced formation of both tau and p-tau granules, which 
showed colocalization with TIA-1 cytoplasmic SGs (Fig. 7b, 
c, zoom-in sections). The average number of SGs in each 
cell was estimated with FIJI-software. We identified a higher 
number of p-tau positive SGs, compared with tau-positive 
Fig. 7  Sodium arsenite induces 
SGs in HeLa cells. a SGs were 
visualized by staining classi-
cal marker of SGs: TIA-1 in 
untreated (control) and sodium 
arsenite-treated (0.6 mM; 
60 min) (stress) cells. The 
cells were counter-stained 
with DAPI to visualize nuclei, 
scale bar = 10 μm. b, c Tau and 
p-tau are recruited into SGs. 
The cells were co-immuno-
stained with primary antibodies 
specific for total-tau, p-tau and 
TIA-1. d The cells positive 
for SGs were calculated with 
FIJI software. More than 80% 
cells were identified positive 
for SGs after stress treatment. 
e Tau and p-tau-positive SGs 
per cell (average no. of SGs) 
were calculated using FIJI 
software. Significance was 
calculated by t-test, *p < 0.05. 
f–i Stress induced increase in 
tau-phosphorylation and TIA-1 
levels. Representative immu-
noblots for TIA-1, total-tau and 
p-tau in control (untreated) and 
stress (arsenite treated) cells. 
Statistical significance was cal-
culated with t-tests **p < 0.01, 
***p < 0.001
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granules (Fig. 7e). Immunoblotting analysis revealed a sig-
nificant increase in the intensity levels of TIA-1 in stress 
(arsenite treatment) cells, compared with controls (Fig. 7f, 
g). There were no significant changes observed for total-tau 
levels (Fig. 7f, h). For p-tau (S199), stress treatment induced 
significant increases in the levels of phosphorylation when 
compared with control (untreated) cells (Fig. 7f, i). This was 
found to be within HMW range (65–250 kDa), suggesting 
tau aggregation [76] under stressful conditions.
To rule out the possibility that the observed increase in 
the tau-phosphorylation in HeLa cells is cell line-specific, 
we also investigated tau-phosphorylation in the neuronal 
cell-line SH-SY5Y and HEK-293 cell line, after stress induc-
tion. Similar increases in the phosphorylated-tau (S199) 
levels in the HMW-range were identified in both cell-lines 
(suppl. Figure 2d–g, online resource). Overall, these results 
indicate that oxidative stress treatment increases tau-phos-
phorylation in all the cell lines tested.
Fig. 8  Recruitment of SFPQ 
into SGs after oxidative stress 
induction in HeLa cells. a 
Localization of SFPQ (green) 
and TIA-1 (red) was investi-
gated using co-immunofluo-
rescence, in sodium arsenite-
treated (0.6 mM; 60 min) 
(stress) and untreated (control) 
cells. Cells were counter-stained 
to visualize nuclei (blue), scale 
bar = 10 μm. b, c SFPQ colo-
calizes with tau/p-tau in SGs 
after sodium arsenite induced 
oxidative stress in HeLa cells. 
Zoomed-in images of stress 
(arsenite treated) cells showing 
the overlap between SFPQ/tau 
in the cytoplasmic granules. 
d Representative immunoblot 
image for SFPQ after stress 
treatment. Intensity levels were 
normalized with β-actin. e The 
densitometric analysis was 
performed with Image Lab soft-
ware. Statistical tests (t-tests) 
were applied in the GraphPad 
prism (6.01), *p < 0.05
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Endogenous SFPQ redistributes into cytoplasm 
and assembles with SGs upon oxidative stress treatment
To discover whether or not endogenous SFPQ forms SGs 
(as colocalization between SFPQ and TIA-1 was observed 
in the human brain), we examined subcellular localization of 
SFPQ after stress induction. SFPQ was primarily localized 
in the nucleus, in the control (untreated) cells, typical locali-
zation of SFPQ (Fig. 8a). Though the nuclear localization of 
SFPQ was not altered after arsenite treatment, stress (arsen-
ite exposure) induced redistribution/translocation of SFPQ 
into granules in HeLa cells (arrowheads, Fig. 8a). To iden-
tify whether these SFPQ granules were actually SGs, HeLa 
cells were co-immuno-stained with the SG marker TIA-1. 
Colocalization was identified between the TIA-1 and SFPQ 
(yellow foci in the cytoplasm) (Fig. 8a, zoom-in section). 
The amount of cytoplasmic SFPQ signal was low because 
labelling only detected endogenous SFPQ, and SFPQ that 
was present in the cytoplasm was largely in the inclusions.
Overall, these results reveal that stress induces cytoplas-
mic redistribution and formation of SFPQ inclusions, which 
colocalize with TIA-1 positive SGs. To further confirm the 
granule formation propensity of SFPQ, we used catGRAN-
ULES algorithm (which assess the granule formation prob-
ability of a given protein on the basis of liquid–liquid phase 
(LLPS) separation property). A score of 1.66 was identified 
even higher than TIA-1(0.973), showing a high probability 
of SFPQ to form granules (suppl. Figure  3c, d, online 
resource).
SFPQ and tau/p‑tau colocalize in the cytoplasmic granules
Recruitment of SFPQ into SGs and localization of tau in 
these SGs, raised the possibility that SFPQ and tau might 
colocalize in SGs and this functional interaction between 
SFPQ and tau might have implications for neurodegenera-
tion. In the control cells, SFPQ was detected predominantly 
in the nucleus, while a translocation was identified in the 
granules in treated (stress-induced) cells. Colocalization 
between SFPQ and tau-5 was observed under both basal 
conditions (control) and in the granules after stress treat-
ment (Fig. 8b, zoom-in section). Likewise, colocalization 
between SFPQ and p-tau (S199) was observed under control 
conditions and in cytoplasmic granules after stress treatment 
(Fig. 8c). Immunoblotting analysis indicated a significant 
increase in the intensity levels of SFPQ after stress induc-
tion, in comparison to control (untreated) cells (Fig. 8d, e).
SFPQ downregulation induced by human tau‑expression
Braak stage-dependent reduction has been reported in the 
levels of SFPQ in the entorhinal cortex (EC) of AD cases 
[39]. In order to explore a direct pathological role of tau on 
Fig. 9  Human tau-induced 
downregulation of SFPQ 
in HeLa cells detected by 
immunoblotting. a–d Repre-
sentative immunoblot images 
for tau, p-tau, SFPQ and TIA-1 
after transient transfection of 
WT-tau or P301L-tau in HeLa 
cells. Densitometric analysis 
was performed with Lab image 
software. Statistical significance 
was estimated with one-way 
ANOVA and Tukey post-hoc 
test for multiple comparisons, 
*p < 0.05
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SFPQ, we expressed human tau, both wild type (WT-tau) 
and mutated-tau (P301L-tau), transiently in HeLa cells.
To assess the expression of tau after transfections, 
immunoblotting analysis was performed at 24- and 48 h 
post-transfection. Protein extracts from transfected cells 
showed an increased level of total-tau and its phospho-
rylated form (S199) (Fig. 9a). There were no significant 
differences observed in the ratio of p-tau to tau between 
WT-tau and P301L-tau transfected cells (Fig. 9b). A trend 
of increased phosphorylation could be noted for WT-tau 
transfected extracts, in comparison to controls (Fig. 9b). 
Interestingly, expression of human-tau led to a significant 
reduction in the levels of SFPQ at 48 h post-transfection in 
WT-tau transfected cells, compared with controls (Fig. 9a, 
c). For P301L-tau expressing cells, a decreasing trend was 
also observed at 48 h post-transfection. There were no 
significant changes observed in the levels of TIA-1 pro-
tein under any of these conditions (Fig. 9a, d). MTS assay 
revealed a significant reduction in cell viability after tau-
expression for both WT-tau and P301L-tau expressing 
cells, with more robust changes for WT-tau expressing 
cells at 48 h post-transfection (suppl. Figure 2i, online 
resource). Overall, immunoblotting analysis indicated that 
tau has a direct effect on SFPQ in the form of reduction, 
which coincides well with the massive reduction of SFPQ 
observed in the rpAD and sCJD patient’s brains.
Proteomic changes associated with  SFPQ downregula‑
tion after  human tau‑expression Human-tau expression 
induced SFPQ downregulation in vitro, in the present study. 
To investigate the combinatorial effect of tau-toxicity and 
SFPQ-reduction hallmarks at 48  h post transfection, we 
Fig. 10  Human tau-expression 
induced proteomic alterations: 
a, b Volcano plots of pairwise 
comparisons (t-tests with 
BH correction), showing the 
-log10-p-values (y-axis) and the 
log2(FC) of the proteins that 
were differentially expressed 
(x-axis) in both WT-tau and 
P301L-tau expressing cells 
in comparison to controls. 
The data points depicted in 
red are showing upregulated 
proteins and blue is represent-
ing downregulated proteins. c 
The heatmap of hierarchical 
clustering analysis of 314 DEPs 
among technical and biological 
replicates generated by Perseus 
software. The Log2-transformed 
expression values of signifi-
cantly DEPs were normalized 
by Z-score. The columns are 
representing samples (tau-
expressing cells: lanes 1–12 
& control: lanes 13–24) and 
rows indicating significantly 
modulated proteins (cluster1, 
up-regulated (red), cluster2, 
down-regulated (green). The 
enriched functional terms 
(Fisher’s exact test with FDR 
multiple test correction) with 
their p-values and FDR values 
are shown on the right side
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employed a quantitative proteomics approach (SWATH-
MS), which has emerged as a powerful technology for inves-
tigation of cellular signalling pathways [35, 44]. SWATH-
MS identified 3597 proteins quantitatively at a critical FDR 
of 1%. Bioinformatics analysis was performed using Per-
seus software to identify differentially expressed proteins 
(DEPs). Proteins showing a corrected Benjamini Hochberg 
corrected p-value < 0.05 were considered differentially 
expressed (Fig. 10a, b). DEPs (314) were divided into two 
sets: the first consisted of 63 up-regulated proteins, and the 
second consisted of 251 down-regulated proteins (suppl. 
Tables 7 and 8, online resource).
A number of bioinformatics tools were used to examine 
enriched functional categories and pathways after human tau 
expression. We performed hierarchical clustering analysis 
and Fisher’s exact test by Perseus software. As shown in 
Fig. 10c, DEPs were clustered hierarchically across all the 
samples (columns). The main branch point in the columns 
separated the tau-expressing cells (Fig. 10c, Lanes 1–12) 
from controls (mock-transfected or non-transfected controls) 
(Fig. 10c, Lanes 13–24). The DEPs (rows) were grouped 
into two main clusters. Cluster-1 included proteins that 
were upregulated in tau-expressing cells (both WT-tau and 
P301L-tau). Most significant functional terms enriched for 
cluster-1 were ion transport and substrate specific transporter 
activity (Fig. 10c: right pane). The downregulated proteins 
(cluster-2) exhibited enrichment for functional-terms related 
to -structural constituent of ribosome and -SRP dependent 
co-translational protein targeting to membrane among other 
terms (Fig. 10c: right panel).
Ingenuity pathway analysis (IPA) Then, ingenuity path-
way analysis (IPA, Qiagen, USA) was performed to iden-
tify major canonical pathways modified after human tau-
expression. According to p-values, the top five significant 
pathways identified in WT-tau expressing cells as compared 
with mock transfected cells were; eukaryotic initiation fac-
tor 2 (eIF2) signalling (p-value = 2.28E−23), regulation of 
eIF4 and p70S6K signalling (p-value = 6.44E−07), mTOR 
signalling (p-value = 5.60E−06), mismatch repair for 
eukaryotes (p-value = 4.93E−05) and proline biosynthesis 
I (p-value = 1.23E−04).
The most significant canonical pathways modu-
lated after P301L-tau expression were EIF2 sig-
nalling (p-value = 3.23E−18), interferon signal-
l ing  (p -va lue  = 2 .86E−04) ,  mTOR s ignal l ing 
(p-value = 9.50E−04), DNA double-strand break repair by 
non-homologous end joining (p-value = 1.11E−03), and 
telomere extension by telomerase (p-value = 1.28E−03). 
Overall, EIF2 signalling was the most-significant pathway 
in both WT-tau and P301L-tau expressing cells.
Disease- and function-based protein networks In addi-
tion to pathway mapping, DEPs were also categorized into 
related disease- and function-based protein networks. The 
most significant networks associated with significantly-
modulated proteins are listed in the supplementary mate-
rial (suppl. Tables 9 and 10, online resource) for both 
WT-tau and P301L-tau expressing cells, respectively. The 
most significant network based on highest percentage of 
focus molecules (score = 61), that is also shared between 
WT- and P301L-tau expressing cells is—RNA damage and 
repair, protein synthesis, cancer—consisting of 27 focus 
molecules, including 60S ribosomal subunit, C7orf50, 
CDK4/6, Eif4g, ERK1/2, IFIT1, Importin beta40s subu-
nit, RPL15, RPL18, RPL18A, RPL19, RPL23A, RPL27A, 
RPL31, RPL32, RPL36, and RPL37A among others. The 
second most-enriched network was—cell morphology, cel-
lular assembly and organization, DNA replication, recom-
bination, and repair network—consisting of 20 focus mol-
ecules from DEPs from proteomic dataset.
Proteomics investigation with functional characteri-
zation has provided a comprehensive overview of major 
alterations associated with tau toxicity and downregulation 
of SFPQ. Analysis of global proteomic alterations revealed 
two major themes—-RNA metabolism and protein synthe-
sis, and -DNA homeostasis-related processes—that were 
significantly altered after human tau-expression.
Dysregulation of SFPQ and TIA‑1 in 3xTg‑mice
Given the long incubation periods of clinically silent neu-
rodegeneration, identification of the modifiable risk fac-
tors at early stages of the disease is crucial. To extend our 
results from the analysis of terminal stage pathology from 
the human brain, a time-dependent expression profile of 
proteomic signatures (tau, p-tau, SFPQ and TIA-1) was 
examined in a mouse model (3xTg mice model of com-
bined Aβ and tau pathology), at 4 time-points correspond-
ing to -3, -6, -9 and 12 months post-inoculation (mpi).
The ratio of p-tau to total-tau was significantly 
increased at the late stage of the disease between the 
experimental (3xTg-inoculated) and age-matched control 
(3xTg-non-inoculated) groups (p < 0.05) (Fig. 11a, b). 
Interestingly, SFPQ expression was significantly increased 
in comparison to controls at early stage after inoculation 
(3mpi) (Fig. 11a, c). At middle stages of the disease, no 
significant changes were observed and a direct reversal (a 
drastic reduction) was identified at late stage (12 mpi) of 
the disease (Fig. 11a, c). Within the sensitivity of the west-
ern blot, the band for SFPQ was not detectable (Fig. 11a), 
which coincided well with the reduced levels of SFPQ in 
the post-mortem brains, in rapidly-progressive forms of 
dementia (rpAD and sCJD).
Two different antibodies detecting C- and N-terminals 
of TIA-1 (TIA-1 abcam: recognizing amino acids 350 
to the C-terminus; TIA-1 sc-166247 recognizing amino 
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acids 37–65 at N-terminus) were used. The expression of 
TIA-1 was significantly decreased at terminal stages of 
the disease (12 mpi) for both antibodies (Fig. 11a, d, e). 
For TIA-1 (C-terminus) antibody, a significant increase 
was observed at the early stage of the disease (3mpi) 
(Fig. 11d). Overall, this time-point expression profile with 
prominent changes in SFPQ, tau and TIA-1 at 3mpi sug-
gest a coordination of these molecules at the very early 
stages of the disease.
Discussion
In this study, we identified and characterised RNA-binding 
proteome from human brain frontal cortex of three neuro-
degenerative disorders—spAD, rpAD, and sCJD (-MM1 
& -VV2 subtypes) as well as control cases—using a brain-
derived RNA-based pull-down approach followed by mass 
spectrometry analysis. One of these proteins—SFPQ is 
dysregulated and dislocated in the post-mortem brains of 
rpAD patients. SFPQ is predominantly a nuclear protein and 
a critical component of neuronal transport granules.
Proteomic study revealed characteristic qualitative and 
quantitative changes in the identified RNA-binding proteome 
in a disease subtype-specific manner. The differential enrich-
ment analysis indicated distinct protein clusters specific to 
each group (Fig. 2g). Overall, this specific enrichment indi-
cates differences in the RNA-RBP interactions in response 
to disease stress. These specific sets of proteins can be of 
potential relevance to identify subtype-specific differences 
in these heterogenous diseases. Of note, RBPome profile of 
rpAD, displayed major similarities with sCJD, compared 
Fig. 11  Temporal expression 
profile of total tau (tau-5), p-tau 
(S199), SFPQ and TIA-1 in 
3xTg mice. a Representative 
immunoblot images showing 
expression of tau, p-tau, SFPQ 
and TIA-1 (C- & N-terminal 
specific antibodies) from AD 
(3xTg-inoculated, n = 4) mouse 
brain cortical tissues at the 
indicated ages (mpi: months 
post inoculation) and respective 
controls (3xTg-non-inoculated, 
n = 4). (*) We are unsure of this 
band. b–e The densitometric 
analyses were performed with 
Image Lab software. Unpaired 
t-tests were performed to 
calculate statistical significance 
at each time point. *p < 0.05, 
**p < 0.01
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with spAD (Fig. 2g). These results suggest that, both forms 
of rapidly progressive dementias (rpAD and sCJD) have 
resemblance in the RBP-mediated neuropathogenesis at the 
terminal stage of the disease.
The functional categories connected with—stress 
response and RNA binding—were enriched in rpAD and 
sCJD groups, compared with control and spAD groups, rep-
resenting a more aggressive dysregulation of RBP-related 
processes. Stress, in various forms, has been associated with 
fast progression not only in AD but also in other neuro-
degenerative disorders, e.g. Huntington’s and Parkinson’s 
diseases [34]. Animal studies have also demonstrated stress 
as a contributing factor to the fast progression of AD, includ-
ing increased accumulation of plaques, and tangle forma-
tion [29, 51]. Recently, stress response has also been linked 
to pathophysiology of tau protein in AD [19, 85], further 
strengthening the hypothesis that stress and post-transcrip-
tional regulatory processes associated with RBPs are an inte-
gral feature of these neurodegenerative disorders.
In line with the previous reports [72], many putative RBP 
candidates were identified in the present study e.g. metabolic 
and catalytic enzymes among others. The identification of 
these putative RBPs in the RNA-binding proteome data set 
points towards a cross-talk between RBPs and other cellular 
proteins to meet the everchanging microenvironment within 
the neurons. Dysregulation of these intricate networks of 
proteins in the neurons may start a cascade of aberrant sign-
aling, eventually leading to neurodegeneration. Many studies 
identifying RBPomes have reported similar putative RBP 
candidates, that have no prior linkage to RNA-associated 
functions [9, 11, 20]. These putative RBP candidates have 
been categorized as enigmRBPs. At this junction, the func-
tions of most of these enigmRBPs as it relates to RNA are 
largely unknown. It is important to note that some of the 
identified putative RBP candidates (e.g. SNG3, HEBP1, 
SV2A) may not have RNA-binding activity themselves. 
They are identified in the current study due to binding with 
other proteins, that do have RNA-binding activity. Addition-
ally, 24 prion-like domain (PLD) containing proteins, fulfill-
ing the criteria to potentially behave as prion-like proteins 
were identified (e.g. SFPQ, BSN, EWS, PRIO, FUBP2) in 
the current study. PLDs are essential for RBP functions and 
enable them to undergo liquid–liquid phase separation, that 
is the basis of formation of higher-order structures, includ-
ing oligomers and granules [13, 63]. PLDs carry out protein 
aggregation in the neurodegenerative disorders, e.g. amyo-
trophic lateral sclerosis (ALS) and, more recently, in AD 
[40, 85, 87].
In the present study, we observed that a PLD-containing 
protein (SFPQ) was exclusively identified in the RBPome of 
rpAD and sCJD groups, suggesting a potential role of SFPQ 
in rapidly progressive dementias. Indeed, we discovered 
dysregulation of SFPQ in association with tau and TIA-1 
proteins, particularly in the rpAD and sCJD post-mortem 
brains.
Recent evidence has shown that neurodegenerative dis-
orders can arise from alterations in dosage and dynamics of 
RBPs [22]. In the present study, down regulation of SFPQ 
at protein level in the frontal cortex of rapidly progressive 
dementias (rpAD and sCJD), suggest that SFPQ dysregula-
tion may have a role in the rapid progression of these dis-
eases. Ke et al. [39] demonstrated Braak stage dependent 
reduction in SFPQ levels in the entorhinal cortex (EC) of 
AD patients. Previously, SFPQ reduction has been linked 
with behavioral anomalies in mice, neuronal loss, and p-tau 
accumulation [37]. In another study, loss of SFPQ was found 
to lead to apoptosis in zebra fish, linking downregulation of 
SFPQ to neuronal cell death [48]. In contrast to the reduction 
at protein level, SFPQ expression was elevated at mRNA 
level in rpAD cases. One plausible explanation for this 
observation could be that transcription of SFPQ is increased 
in order to compensate for loss of SFPQ at the protein level. 
The elevated mRNA levels of SFPQ could also contribute 
directly to neurodegeneration: this excessive mRNA may 
sequester many proteins necessary for other cellular signal-
ling, leading to translation defects among others, as has been 
noted for some other neurodegenerative disease associated 
proteins [30, 69, 79].
Further, the present study discovered a drastic nuclear 
depletion of SFPQ in the frontal cortex of rpAD cases. Spe-
cifically, higher dislocation rate (91% of cells) identified 
in rpAD cases in comparison to spAD (51%) and controls 
(43%), suggests an important role of SFPQ in the pathology 
of rpAD. A complete dislocation of SFPQ in the hippocam-
pus of AD patients has been reported previously [39]. While, 
Lu et al. [49], demonstrated a moderate dislocation in AD 
brains, which was consistent with the observations regarding 
spAD in the present study. Based on data from the current 
study, from the frontal cortex and literature reports (show-
ing dislocation in hippocampus), it can be concluded that 
dislocation of SFPQ is an important feature of Alzheimer’s 
pathology, and different brain regions have variable intensity 
of SFPQ dislocation. Increased dislocation in rpAD cases 
may be due to higher cell death (through apoptosis), as cyto-
plasmic localization of SFPQ has been observed in apoptotic 
cells [71]. SFPQ is predominantly a nuclear protein involved 
in multiple functions in the neurons, including transcrip-
tion, alternative splicing, DNA-damage and repair, and RNA 
transport [41, 88]. Overall, dysregulation and nuclear deple-
tion of SFPQ observed in rpAD cases, could contribute to 
neurodegeneration by both: loss of nuclear functions [49], 
and gain of toxic functions in the cytoplasm. To the best of 
our knowledge, this is the first study demonstrating dysregu-
lation of SFPQ at both protein and mRNA level, and its dis-
location from the nucleus in the frontal cortex of specifically 
rpAD cases. One potential limitation of these findings is 
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that the regulation of proteomic targets could not be studied 
with reference to gender dependent differences due to lim-
ited availability of our cohort of control and patient cases. 
Given the explorative nature of the present study, further 
studies are needed with higher number of samples for a tar-
geted approach.
SFPQ nuclear dislocation was associated with its cyto-
plasmic colocalization with SG-marker-TIA-1, p-tau tangles 
and oligomeric-tau in brain lesions of rpAD cases. Signifi-
cant colocalization between SFPQ and p-tau in the rpAD 
brain in comparison with spAD, suggests involvement of dif-
ferent pathological mechanisms in subtypes of AD. Associa-
tion of SFPQ with oligomeric-tau in both spAD and rpAD 
provides an intimate link of SFPQ to pathological tau. In 
line with the findings from the human brain, SFPQ and p-tau 
translocated from the nucleus and assembled into cytoplas-
mic TIA-1-positive SGs in response to oxidative stress stim-
uli in the cultures (HeLa cells). In the current study, HeLa 
cells were used as an appropriate model for stress induction. 
Several models have been used to understand SGs at cellular 
level, including recombinant cell lines (Aulas and Vande 
Velde [5]. A great deal of our knowledge of these cytoplas-
mic membrane-less foci (SGs) originates from studies in 
HeLa cells (154 publications, according to Aulas and Vande 
Velde [5]. Although, this is a non neuronal cell line, the cell 
line worked for the current study due to several advantages 
including; -large cytoplasmic volume of HeLa cells com-
pared to other cell lines which allows accurate identification 
of cytoplasmic SGs, they are easy to maintain in culture and 
-reliably result in high transfection efficiency [8].
These findings from the current study indicate a role of 
SFPQ in the stress response under physiological conditions. 
The identification of SFPQ in the SG-interactome of  U2OS 
cells [38], further confirms the involvement of SFPQ in the 
stress response. Redistribution and colocalization of SFPQ 
in cytoplasmic TIA-1-SGs provides a possible mechanism 
of SFPQ depletion/dislocation through pathological SGs. 
Pathological and persistent TIA-1-SGs have been implicated 
in AD [4]. This redistribution of SFPQ has been linked to 
cell cycle arrest [50], apoptosis [28, 71], and splicing abnor-
malities. All these evidences suggest that cells may use cyto-
plasmic activities of SFPQ as a gauge to cope with cellular 
crisis, while it might lead to more demise for the nuclear 
functions of SFPQ.
Cytoplasmic co-aggregation of tau protein with some 
splicing factors has been reported for both sporadic and 
familial AD cases [7, 12, 25]. In the current study, a sig-
nificant cytoplasmic colocalization between SFPQ and p-tau 
(S199) in the rpAD brains, in comparison to spAD cases, 
suggest a change in the nuclear-functions of these proteins. 
We speculate that, at initial stages of disease, kinases can 
phosphorylate not only tau protein but also SFPQ. This 
phosphorylation can switch their localization, redistributing 
them either to the nuclear envelope or cytoplasm [49] and 
results in an overall “depletion’’ from the nucleus. As phos-
phorylation at C-terminal tyrosines leads to accumulation of 
SFPQ at the nuclear envelop or cytoplasm [50, 59]. Further, 
a complete depletion of nuclear-tau has been reported in 
the hippocampal neurons of AD patients [33]. Previously, 
pathological SGs have been linked to mislocalization of tau, 
FUS and TDP-43 [15, 24, 46, 85, 89].
Reduction in SFPQ levels after human-tau expression 
(0N4R), at 48 h post transfection in HeLa cells confirmed 
a causal role of tau in the downregulation of SFPQ. There 
were no significant changes observed in SFPQ levels at 
24 h post transfection, in line with previous findings in SH-
SY5Y cells [39]. Quantitative-MS (SWATH-MS) analysis 
from this model highlighted two major themes (DNA dam-
age and repair and RNA-metabolism) that were altered as 
a result of combinatorial effect of tau-toxicity and SFPQ 
downregulation. To date, any role of tau protein in the main-
tenance of telomere has not been reported, the observed dis-
turbances in the telomere maintenance, can be attributed to 
SFPQ reduction hallmarks. Overall, these findings confirm 
nuclear loss of function-abnormalities associated with SFPQ 
downregulation.
Finally, the present study uncovered that expression of 
SFPQ and TIA-1 is significantly elevated already at the early 
stage (3 mpi) in 3xTg mice model of combined Aβ and tau 
pathology, suggesting that these proteins could be of potential 
significance as early disease-modifying targets. This upregu-
lation (of SFPQ and TIA-1) in mice is consistent with the 
acute-phase oxidative stress-induced increase in SFPQ and 
TIA-1 levels in HeLa cells, suggesting that at early stages 
of the disease stress associated with pre-tangle pathology 
might induce these changes [64]. A drastic reduction in SFPQ 
levels at late stage (12mpi) in 3xTg mice—in corroboration 
with reduced expression of SFPQ in post-mortem brains of 
both rapidly progressing diseases (rpAD and prion diseases); 
indicates that SFPQ could be of potential relevance to iden-
tify rapidly progressing forms of dementia. SFPQ reduction 
(knock down) leads to a decreased expression of amyloid 
precursor protein (APP) [77] in neuronal cells. Given the 
presence of extensive Aβ and tau pathology by 12 mpi and 
tau dependent reduction in SFPQ levels in our cellular study, 
indicates this reduction as a combinatorial effect of Aβ and 
tau pathology. Furthermore, a similar reduction in the levels 
of TIA-1, in both mice (at late stage of the disease) and spAD 
cases, suggest a compensatory/protective response adopted 
by the neurons. As reduction in TIA-1 (haplosufficiency) has 
been proven to be protective against neurodegeneration [4]. 
In contrast, a failure to adopt this protective response in rpAD 
cases, identified as a significant increase in TIA-1 levels in 
rpAD cases, in comparison to spAD cases, suggests higher 
neurodegeneration in rpAD cases.
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Conclusion
Overall, our findings provide a comprehensive RBPome 
map (of spAD, rpAD and sCJD) and opens many new tar-
gets for exploration. The study has identified SFPQ, tau 
and TIA-1 as critical factors involved in rpAD pathology 
(Fig. 12). Co-immunofluorescence analysis demonstrated 
complete nuclear depletion of SFPQ, particularly in the 
rapidly progressive AD cases. This nuclear depletion was 
concomitantly associated with its cytoplasmic colocali-
zation with p-tau (S199) tangles and oligomers of tau. 
In parallel with human brain findings, our in vitro study 
(cellular model of stress) clearly demonstrated the translo-
cation of SFPQ and p-tau into cytoplasmic TIA-1-positive 
SGs, upon oxidative stress treatment. The expression of 
human tau (tau pathology model) in vitro induced signifi-
cant downregulation of SFPQ, suggesting a causal role of 
tau in the downregulation of SFPQ. Finally, the 3xTg mice 
model study uncovered specifically very early changes 
(3mpi) of target proteomic signatures. The expression of 
SFPQ and TIA-1 was already significantly elevated at the 
early stages of the disease in the 3xTg mice model, sug-
gesting that these proteins could be of potential signifi-
cance as early therapeutic targets.
The re-establishment of the normal architecture of the 
nucleus, by treating SFPQ dislocation/depletion, could be 
an interesting candidate for future therapeutic research 
strategies. Results from the current study extend the patho-
logical features of tau beyond microtubular and somato-
dendritic compartments to the nuclear processes.
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